SEC Form 4 · accession 0001104659-15-018603
STEMLINE THERAPEUTICS INC · STML
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kenneth Hoberman
Officer — Chief Operating Officer
Period of report
Mar 6, 2015
Accepted (ET)
Mar 10, 2015 · 5:54 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001264587
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Mar 6, 2015 | A | 24,379 | $0.00 | A | 112,321 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (right to buy)F2 | $15.75 | Mar 6, 2015 | A | 69,201 | A | Mar 6, 2016 | Mar 6, 2025 | Common Stock | 69,201 | 69,201 | D |
Explanation of responses
- F1The 24,379 restricted shares will vest in four installments as follows: 6,095 shares on March 6, 2016; 6,095 shares on March 6, 2017; 6,095 shares on March 6, 2018; and 6,094 shares on March 6, 2019.
- F2The 69,201 options will vest in four installments as follows: 17,301 shares on March 6, 2016; 17,300 shares on March 6, 2017; 17,300 shares on March 6, 2018; and 17,300 shares on March 6, 2019.